Loading…
← CockpitCompetitor Analysis › 301230.SZ PharmaResources (Shanghai) Co., Ltd Class AOpen in the cockpit ↗

PharmaResources (Shanghai) Co., Ltd Class A301230.SZCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services
Momentum weak 30
Mkt cap
$695M
US dollars, full cap
$/day
$90.5M
20-day average traded
Fwd P/E
76.5×
forward earnings
ROIC−WACC
-4.9 pp
WACC 11.2%
Hurdle
+19 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥27.20
1D-4.2%
1W-20.5%
1M-24.0%
3M-30.4%
6M-9.8%
YTD+18.4%
1Y+5.2%
ATR %10.0%
52w lowhigh48.0% off high

What PharmaResources (Shanghai) does

Employees: 1,155

PharmaResources (Shanghai) at a glance

Size PharmaResources (Shanghai) (301230.SZ) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $695M, the 2914th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥27.20 on 18 Nov 2026.

Performance Over six months the shares fell 9.8%, against -7.9% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 8.9% over the last twelve months (peer median +6.0%); the operating margin is 0.3% (peer median 4.7%).

Valuation It trades at 76.5× forward earnings against a peer median of 18.5× (3rd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 39% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.9 points below its cost of capital (11.2% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026301230.SZ 91Peer median 89
Six months, rebased to 100: PharmaResources (Shanghai) against the median of its 20 peers (local-currency closes).

PharmaResources (Shanghai) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥724MCN¥688MCN¥543MCN¥488MCN¥477M
Revenue growth—+27%+11%+2%—
Gross profitCN¥233MCN¥146MCN¥99.1MCN¥138MCN¥166M
EBITDAn/aCN¥118MCN¥69.2MCN¥76.6MCN¥97.8M
Net incomeCN¥28.6MCN¥34.3MCN¥17.1MCN¥37.6MCN¥67.2M
Free cash flowCN¥94.1MCN¥92.3M-CN¥25.1M-CN¥221M-CN¥116M
Capital expenditureCN¥79.0MCN¥43.3MCN¥109MCN¥248MCN¥124M
Total debtCN¥144MCN¥167MCN¥188MCN¥215MCN¥111M

Quarterly statements and history in the cockpit →

PharmaResources (Shanghai) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%-10%0%+10%688150AUBCCP002915688707301508CGY300949JSG300492RWS30068897572874301228001207300860GUBRA688170301230.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. PharmaResources (Shanghai) is the large dot.

Fundamentals: revenue growth against valuation

-50%0%0×200×400×600×688150AUBCCPCGYJSG300688300860GUBRA688170301230.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PharmaResources (Shanghai) is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%AUBCCPCGYJSG3004929757001207300860301230.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. PharmaResources (Shanghai) is the large dot.

PharmaResources (Shanghai) competitors and peer comparison

How PharmaResources (Shanghai) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PharmaResources (Shanghai) against its 20 peers (data as of 18 Nov 2026)
Measure301230.SZPeer medianRank in peer set
1-month return-24.0%-7.2%lowest of 21
6-month return-9.8%-7.9%10th lowest of 21
Distance from 52-week high-48.0%-30.3%8th lowest of 21
Revenue growth (TTM)+8.9%+6.0%8th highest of 21
Operating margin0.3%4.7%8th lowest of 21
Forward P/E76.5×18.5×3rd most expensive of 16
Growth the price implies (Req g, 7 yrs)39.0%5.5%most demanding of 12
Growth delivered (Del g)+19.5%+12.4%2nd highest of 12
Hurdle (Req g minus delivered)+19.5 pp-9.2 pp2nd most demanding of 12
ROIC minus cost of capital-4.9 pp-2.3 pp9th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PharmaResources (Shanghai) 301230.SZChina$695M-10%+9%0%76.5×39.0%+19.5%
Shaanxi Lighte Optoelectronics Material 688150.SSChina$692M-56%+14%39%36.4×n/an/a
Aubay AUB.PAFrance$690M-7%+27%9%12.9×2.6%+7.1%
Credit CCP.AXAustralia$704M+39%+7%26%9.4×1.9%+11.1%
Zhejiang Zhongxin Fluoride Materials 002915.SZChina$683M-41%+8%2%59.0×n/an/a
Guizhou Zhenhua E-Chem 688707.SSChina$681M-44%+15%-17%n/a1.9%+6.6%
China Machinery Huanyu Certification & Inspection 301508.SZChina$681M-24%+10%21%n/a5.5%+15.4%
Calian CGY.TOCanada$677M+2%+16%6%18.5×13.7%+12.4%
Shenzhen L&A Design 300949.SZChina$715M+98%0%-28%n/an/an/a
Johnson Service JSG.LUnited Kingdom$674M+7%+2%11%10.8×8.2%+18.4%
Huatu Cendes 300492.SZChina$671M-50%-8%-2%n/a13.9%+91.2%
RWS RWS.LUnited Kingdom$669M+41%-1%4%10.4×11.9%+14.2%
Dark Horse Technology 300688.SZChina$723M+12%-32%-33%576.0×n/an/a
Funai Soken 9757.TJapan$724M+10%+5%25%16.2×-8.7%+5.9%
Yokorei 2874.TJapan$663M-9%+4%5%23.1×n/an/a
SEP Analytical (Shanghai) 301228.SZChina$663M-42%+5%-9%n/an/an/a
Cuscal CCL.AXAustralia$728M+17%+19%12%18.1×n/an/a
Shandong Link Science and Technology 001207.SZChina$733M-24%+7%13%11.6×-5.5%+18.9%
Funshine Culture 300860.SZChina$739M0%-49%-35%24.2×21.5%-24.6%
Gubra A/S GUBRA.CODenmark$651M-21%-90%-72%103.5×n/an/a
Suzhou Delphi Laser 688170.SSChina$649M-42%+20%1%71.2×n/an/a

Questions

Which companies are PharmaResources (Shanghai)'s closest peers?
The cockpit's peer set: Shaanxi Lighte Optoelectronics Material (688150.SS), Aubay (AUB.PA), Credit (CCP.AX), Zhejiang Zhongxin Fluoride Materials (002915.SZ), Guizhou Zhenhua E-Chem (688707.SS), China Machinery Huanyu Certification & Inspection (301508.SZ), Calian (CGY.TO), Shenzhen L&A Design (300949.SZ).
Is PharmaResources (Shanghai) expensive compared with its peers?
On forward p/e it trades at 76.5× against a peer median of 18.5×, 3rd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 39% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has PharmaResources (Shanghai) stock performed?
Over six months to 18 Nov 2026 the shares returned -9.8% against -7.9% for the median peer; over one year +5.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.